Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt

US LGNZZ

NoneUSD
0.00(0%)

Last update at 2026-06-04T18:20:39.363894Z

Day Range

--
LowHigh

52 Week Range

0.080.18
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap10.90M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA30.94M
  • Revenue TTM153.60M
  • Revenue Per Share TTM8.95
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 36.01M 47.30M -10.53800M 796.64M 173.33M
Minority interest - - - - -
Net income -5.21900M 37.01M -2.98500M 629.30M 143.32M
Selling general administrative 70.06M 57.48M 64.44M - -
Selling and marketing expenses - - - - -
Gross profit 196.25M 214.96M 156.00M -5.72100M 163.73M
Reconciled depreciation - - - - -
Ebit 37.81M 78.89M 25.84M 832.38M 221.61M
Ebitda 89.36M 28.56M 31.99M - -
Depreciation and amortization 51.55M -50.33700M 6.14M - -
Non operating income net other - - - 25.31M 57.88M
Operating income 37.81M 78.89M 25.84M 807.08M 163.73M
Other operating expenses 193.21M 198.24M 208.11M 812.80M -
Interest expense 1.80M -18.74000M 27.42M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 41.23M 10.29M 7.55M 167.34M 30.01M
Total revenue 196.25M 277.13M 186.42M 120.28M 251.45M
Total operating expenses 193.21M 136.06M 177.69M -812.79700M -
Cost of revenue - 62.18M 30.42M 126.00M 87.73M
Total other income expense net -1.79900M -31.59700M -36.38300M - -
Discontinued operations - - - - -
Net income from continuing ops - - - 629.30M 143.32M
Net income applicable to common shares - - - 629.30M 143.32M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 762.67M 1301.38M 1362.29M 1494.91M 1260.80M
Intangible assets 342.45M - 595.33M 230.54M 251.25M
Earning assets - - - - -
Other current assets 3.40M -330.24400M 6.04M 63.07M 89.19M
Total liab 165.18M 479.75M 652.76M 727.68M 699.89M
Total stockholder equity 597.49M 821.63M 709.52M 767.23M 560.91M
Deferred long term liab - - - 32.94M -
Other current liab 92.43M 30.58M 65.01M 4.75M 9.00M
Common stock 0.02M - 0.02M 0.02M 0.02M
Capital stock - - - - -
Retained earnings 450.86M - 391.95M 400.11M -229.19700M
Other liab - - - - -
Good will 105.67M - 189.66M 95.23M 86.65M
Other assets - - - - -
Cash 45.01M 341.11M 47.62M 71.54M 117.16M
Cash and equivalents - - - - -
Total current liabilities 98.81M 41.66M 100.11M 17.00M 82.25M
Current deferred revenue 0.35M 11.00M 29.43M - -
Net debt 42.74M 10.69M -45.73400M - -
Short term debt 0.71M 0.09M 1.89M - 49.86M
Short long term debt - - - - -
Short long term debt total 87.75M 351.80M 1.89M - -
Other stockholder equity 147.59M 821.63M 318.36M -0.21600M -1.02400M
Property plant equipment - - - 7.18M 5.37M
Total current assets 263.60M 464.75M 500.56M 1123.64M 870.54M
Long term investments - - - - -
Net tangible assets - - - 441.46M 223.01M
Short term investments 166.86M 341.11M 363.57M 939.99M 601.22M
Net receivables 35.04M 85.45M 56.85M 41.75M 55.85M
Long term debt - - - 638.96M 609.86M
Inventory 13.29M 27.33M 26.49M 7.30M 7.12M
Accounts payable 5.31M - 3.78M 12.26M 23.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.98400M - -0.80100M - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 400.11M -229.19700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 14.92M 784.57M 55.41M 12.71M 0.47M
Deferred long term asset charges - - - - -
Non current assets total 499.07M 836.63M 861.73M 25.61M 46.52M
Capital lease obligations - - - - -
Long term debt total - - - 638.96M 609.86M
Breakdown 2022-12-31 2019-12-31 2018-12-31 2009-09-30 2008-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2019-12-31 2018-12-31 2009-09-30 2008-12-31
Investments - -326.81700M -405.52600M - -
Change to liabilities - -4.39800M -4.54200M - -
Total cashflows from investing activities - 466.92M -423.26900M - -
Net borrowings - -27.32300M 515.40M - -
Total cash from financing activities -275.99000M -485.17200M 328.58M - 12.31M
Change to operating activities - - - - -
Net income -33.36100M 629.30M 143.32M - -42.31400M
Change in cash 25.48M -47.59000M 99.38M - -1.54200M
Begin period cash flow 12.60M - - 12.60M 14.14M
End period cash flow 38.08M 12.60M - - 12.60M
Total cash from operating activities 137.85M -29.33600M 194.06M - -33.07300M
Issuance of capital stock - - - - -
Depreciation 51.55M 38.08M 53.22M - 2.07M
Other cashflows from investing activities - 796.29M -16.85600M - -
Dividends paid - - - - -
Change to inventory 12.06M -2.06100M -2.55900M - -
Change to account receivables 55.32M - - - -
Sale purchase of stock - -450.43100M -42.77900M - -
Other cashflows from financing activities -14.98700M -7.41800M -144.04000M - 5.00M
Change to netincome - -717.86800M 9.08M - -
Capital expenditures 17.92M 2.55M 0.89M 0.00000M 0.53M
Change receivables - 25.46M -29.54400M - -
Cash flows other operating - 2.15M 25.09M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -47.59000M 99.38M - -
Change in working capital 38.65M - - - 3.21M
Stock based compensation 60.28M - - - 3.94M
Other non cash items - - - - 0.48M
Free cash flow 119.93M - - - -33.59800M

Peer Comparison

Sector: Industry:

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LGNZZ
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt		 - -% - - - - - 0.60 -1.1488
DOGEF
Orsted A/S		 -1.046 4.02% 25.00 28.82 0.66 6.50 0.07 3.88 15.58
NCRRP
NCR Corp Pref A		 - -% 1002.00 1034.35 - - -
TBB
AT&T Inc. 5.35% GLB NTS 66		 - -% 20.76 4.60 - - -
CCZ
Comcast Holdings Corp		 0.21 0.32% 65.15 55.07 - - -

Reports Covered

Stock Research & News

View All

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.